Tau positron emission tomographic imaging in aging and early Alzheimer disease

Annals of Neurology

Volumn 79, Issue 1, 2016, Pages 110-119

  Johnson, Keith A ^a,b   Schultz, Aaron ^a   Betensky, Rebecca A ^a,c   Becker, J Alex ^a   Sepulcre, Jorge ^a,b   Rentz, Dorene ^a,b   Mormino, Elizabeth ^a   Chhatwal, Jasmeer ^a,b   Amariglio, Rebecca ^a,b   Papp, Kate ^a,b   Marshall, Gad ^a,b   Albers, Mark ^a,b   Mauro, Samantha ^a   Pepin, Lesley ^a   Alverio, Jonathan ^a   Judge, Kelly ^a   Philiossaint, Marlie ^a   Shoup, Timothy ^a   Yokell, Daniel ^a,b   Dickerson, Bradford ^a,b   Gomez Isla, Teresa ^a,b   Hyman, Bradley ^a,b   Vasdev, Neil ^a,b   Sperling, Reisa ^a,b   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLORTAUCIPIR F 18; PITTSBURGH COMPOUND B; TAU PROTEIN; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; ANILINE DERIVATIVE; BIOLOGICAL MARKER; CARBOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BOLUS INJECTION; BRAIN LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; HUMAN; IMAGING SOFTWARE; INFERIOR TEMPORAL GYRUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TRANSPORT; BRAIN CORTEX; COGNITIVE DEFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; TEMPORAL LOBE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; CARBOLINES; CEREBRAL CORTEX; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; TEMPORAL LOBE; THIAZOLES;

EID: 84956583549     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24546     Document Type: Article

References (34)

1. Hyman BT, Phelps CH, Beach TG, et al.; National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
2. Nelson PT, Alafuzoff I, Bigio EH, et al.; Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381.
3. Klunk WE, Engler H, Nordberg A, et al.; Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-319.
4. Clark CM, Pontecorvo MJ, Beach TG, et al.; Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669-678.
5. Rinne JO, Wong DF, Wolk DA, et al.; [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 2012; 124: 833-845.
6. Xia C-F, Arteaga J, Chen G, et al.; [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013; 9: 666-676.
7. Chien DT, Bahri S, Szardenings AK, et al.; Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34: 457-468.
8. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC,. Tau imaging: early progress and future directions. Lancet Neurol 2015; 14: 114-124.
9. Okamura N, Furumoto S, Fodero-Tavoletti MT, et al.; Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014; 137: 1762-1771.
10. Harada R, Okamura N, Furumoto S, et al.; Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging 2013; 40: 125-132.
11. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, et al.; In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging 2014; 41: 816-826.
12. Yesavage JA, Brink TL, Rose TL, et al.; Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 17: 37-49.
13. Wechsler D,. WMS-R: Wechsler Memory Scale-revised. San Antonio, TX: Psychological Corp, 1987.
14. Folstein MF, Folstein SE, McHugh PR,. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
15. Morris JC,. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
16. Becker JA, Hedden T, Carmasin J, et al.; Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 2011; 69: 1032-1042.
17. Amariglio RE, Becker JA, Carmasin J, et al.; Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 2012; 50: 2880-2886.
18. Mormino EC, Betensky RA, Hedden T, et al.; Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014; 82: 1760-1767.
19. Albert MS, Dekosky ST, Dickson D, et al.; The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
20. McKhann GM, Knopman DS, Chertkow H, et al.; The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
21. Shoup TM, Yokell DL, Rice PA, et al.; A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm, 2013; 56: 736-740.
22. Braak H, Alafuzoff I, Arzberger T, et al.; Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
23. Braak H, Braak E,. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-357.
24. Delacourte A, Sergeant N, Wattez A, et al.; Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol 2002; 37: 1291-1296.
25. Fischl B, Salat DH, van der Kouwe AJ, et al.; Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004; 23 (suppl 1): S69-S84.
26. Logan J,. Graphical analysis of reversible radioligand binding from time-activity measurements. J Cereb Blood Flow Metab 1990; 10: 740-747.
27. Hedden T, Van Dijk KRA, Becker JA, et al.; Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009; 29: 12686-12694.
28. Arriagada PV, Marzloff K, Hyman BT,. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992; 42: 1681-1688.
29. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT,. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42 (3 pt 1): 631-639.
30. Gõmez-Isla T, Price JL, McKeel DW Jr, et al.; Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491-4500.
31. Marquie M, Normandin M, Vanderburg C, et al.; Towards the validation of novel PET tracer T807 on postmortem human brain tissue samples. Paper presented at: 9th Human Amyloid Imaging Conference; January 14-16, 2015; Miami, FL.
32. Serrano-Pozo A, Qian J, Monsell SE, et al.; Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol 2013; 72: 1182-1192.
33. Nelson PT, Abner EL, Schmitt FA, et al.; Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol 2009; 68: 774-784.
34. Crary JF, Trojanowski JQ, Schneider JA, et al.; Primary age-related taupathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128: 755-766.